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Modelling the Role of Incarceration in HCV Transmission and Prevention Amongst People Who 
Inject Drugs in Rural Kentucky 
Background: People who inject drugs (PWID) experience high incarceration rates, with current/recent 
incarceration being associated with increased hepatitis C virus (HCV) transmission. We assess the 
contribution of incarceration to HCV transmission amongst PWID in Perry County (PC), Kentucky, 
USA, and the impact of scaling-up community and in-prison opioid substitution therapy (OST), 
including the potential for reducing incarceration.  
Methods: A dynamic model of incarceration and HCV transmission amongst PWID was calibrated in 
a Bayesian framework to epidemiological and incarceration data from PC, incorporating an empirically 
estimated 2.8-fold (95%CI: 1.36-5.77) elevated HCV acquisition risk amongst currently incarcerated 
or recently released (<6 months) PWID compared to other PWID. We projected the percentage of new 
HCV infections that would be prevented among PWID over 2020-2030 if incarceration no longer 
elevated HCV transmission risk, if needle and syringe programmes (NSP) and OST are scaled-up, 
and/or if drug use was decriminalised (incarceration/reincarceration rates are halved) with 50% of 
PWID that would have been imprisoned being diverted onto OST. We assume OST reduces 
reincarceration by 10-42%. 
Results: Over 2020-2030, removing the effect of incarceration on HCV transmission could prevent 
42.7% (95% credibility interval: 15.0-67.4%) of new HCV infections amongst PWID. Conversely, 
scaling-up community OST and NSP to 50% coverage could prevent 28.5% (20.0-37.4%) of new 
infections, with this increasing to 32.7% (24.5-41.2%) if PWID are retained on OST upon incarceration, 
36.4% (27.7-44.9%) if PWID initiate OST in prison, and 45.3% (35.9-54.1%) if PWID are retained on 
OST upon release. Decriminalisation (with diversion to OST) could further increase this impact, 
preventing 56.8% (45.3-64.5%) of new infections. The impact of these OST interventions decreases by 
2.1-28.6% if OST does not reduce incarceration. 
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Conclusion: Incarceration is likely to be an important contributor to HCV transmission amongst PWID 
in PC. Prison-based OST could be an important intervention for reducing this risk.  
Keywords: Hepatitis C virus, people who inject drugs, incarceration, prison, mathematical 
modelling, harm reduction 
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Introduction 
The U.S. has the largest global prison population (2,121,600)(1) and one of the largest populations of 
people who inject drugs (PWID, estimated 2,248,500)(2). In the U.S., an estimated 3.4-6.0 million 
people have been exposed to HCV, with the HCV sero-prevalence in correctional facilities (~23.1%(3)) 
far exceeding that of the general population (1.7%(3)). PWID also have a high HCV sero-prevalence 
in the U.S., with most new HCV infections occurring within this group(4). Recently, an epidemic of 
prescription opioid abuse in rural regions of the U.S.(5) led to an increase in the number of PWID(6) 
and an upsurge in reported cases of acute HCV infection(7).  
 
In Perry County (PC), a rural county in Appalachian Kentucky, data from an on-going longitudinal 
cohort of PWID demonstrated a high sero-prevalence (58%) and incidence (19.4 per 100 person-years) 
of HCV among PWID. Furthermore, there is low coverage of opioid substitution therapy (OST, 4.7% 
coverage among community PWID(8)) and needle and syringe programmes (NSP) only initiated in 
2018(9).  
 
Globally, PWID are frequently incarcerated (58% ever incarcerated(2)), with data from Perry 
County(10) suggesting that most PWID in that setting have ever been incarcerated (86%) and are 
incarcerated repeatedly (average 10 previous incarcerations) with short sentence lengths (average 3.4 
months). Our recent systematic review suggests that recent incarceration could increase the risk of HCV 
acquisition among PWID by 62%, with data from PC suggesting a 2.8-fold increase in risk in that 
setting(11). Compounding this, there are no interventions provided for incarcerated PWID or targeted 
to recently released PWID in PC.  
 
The high level of HCV transmission in PC, paired with high levels of incarceration and very low levels 
of interventions highlight an urgent need to develop strategies to reduce the transmission of HCV and 
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levels of incarceration in this setting. This is crucial if there is to be any hope for rural US settings such 
as Perry County to reach the WHO goal of eliminating HCV as a public health threat by 2030(12). Prior 
modelling has generally only considered the need for community prevention and treatment 
interventions for reaching the WHO targets in PWID(12-15), with only our analysis from Scotland 
considering the role of prison-based interventions(16). In this analysis, we focus on evaluating the 
possible importance of both community OST (and NSP) and prison-based OST for helping PC achieve 
the WHO HCV elimination targets. We include direct benefits of OST on reducing HCV transmission 
risk(17), and the possible effect of OST on reducing incarceration rates based on data that it reduces 
criminal activity(18-21), criminal convictions (22-24) and re-incarceration(25, 26). 
Methods 
Throughout this paper, we use the term incarceration to refer to the act of detention of people 
in prisons, jails (the most common form of detention for the modelled population), or other 
closed settings and use the term prison to refer to any such setting where someone might be 
detained, including jail. 
Model description 
We adapted an existing dynamic, deterministic model of incarceration and HCV transmission amongst 
current PWID(16). The adapted model stratifies PWID by incarceration state (never incarcerated, 
currently incarcerated, recently released – last 6 months, previously incarcerated – released > 6 months 
ago) and HCV status (susceptible, chronically infected). The model additionally stratifies PWID by 
OST and NSP status (not on OST or NSP, on OST or NSP only, or on both OST and NSP; Figure 1) in 
the community and prison. A full model description is in the supplementary materials.  
All PWID enter the model as susceptible and not on OST or NSP, with a proportion entering each of 
the incarceration states. PWID are recruited onto and lost to follow-up from OST or NSP at constant 
rates which are independent of the other intervention state. In the status quo model, all PWID cease 
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OST and NSP use upon incarceration, as currently occurs in PC. However, in some of the modelled 
intervention scenarios PWID are retained on OST upon incarceration. Community PWID experience 
reduced rates of incarceration whilst on OST(25). Depending on the intervention scenario modelled, 
PWID either leave OST or stay on OST upon release from prison. 
 
PWID acquire and transmit HCV in their given setting (prison or community) with susceptible PWID 
becoming infected at a rate proportional to the chronic prevalence in their setting and the HCV 
transmission rate. The HCV transmission rate is reduced for PWID on OST and/or NSP and elevated if 
PWID are currently incarcerated or have been recently released (<6 months) from prison. The model 
assumes random mixing between all PWID risk subgroups within the community or prison.  
 
Model parameterisation and calibration 
The model was parameterised and calibrated to the HCV epidemic among PWID in Perry County, 
Kentucky, with most parameter estimates coming from the Social Networks Among Appalachian 
People study (denoted as ‘SNAP’), the methods of which have been described previously(10). The 
SNAP study recruited 503 illicit drug users (78% were initially PWID) through respondent driven 
sampling (RDS) in Perry County between November 2008-September 2010 and followed them up 
between every six and eighteen months until 2014/15. 
 
Model parameterisation and calibration comprised two steps. First, the incarceration dynamics were 
parameterised and calibrated to self-reported incarceration history data. This was done with an adapted 
incarceration model (see supplementary materials) that simulated a cohort of PWID progressing 
through their injecting career with the sub-model (Supplementary Figure S1) being calibrated to 
incarceration-related data. The HCV transmission component of the model was then parameterised and 
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calibrated, using incarceration parameters from the first step and incorporating an increase in the 
initiation rate of new PWID between 1990 and 2000. 
 
Step 1: Parameterising and calibrating the incarceration sub-model 
We tracked a simulated cohort of 1,000 PWID for 18 years from initiation of injecting to calibrate the 
model’s incarceration and reincarceration rates, and proportion of new PWID initiating injecting in 
each incarceration state. An approximate Bayesian computation sequential Monte Carlo scheme(27) 
was used to obtain a sample of 5,000 incarceration-related parameter sets (prior and posterior parameter 
ranges in Table 1) that fit the SNAP incarceration data on the proportions of community PWID who 
have ever been incarcerated and the mean number of incarcerations by duration injecting (data shown 
in Figure 2). Full details of this calibration process are in the Supplementary materials. Figure 2 shows 
the model fits to data on the proportion of PWID ever incarcerated and their mean number of 
incarcerations by duration of injecting. 
 
Figure 2 here 
 
Step 2: Parameterising and calibrating the full model  
SNAP data suggest community OST coverage was 4.7% (95% CI: 3.8-5.8%) in 2009, which remained 
stable throughout the study, with SNAP data suggesting a mean duration of 5.6 months (95%CI: 3.3-
9.1 months) on OST. There was negligible NSP. Two studies from Australia and Canada suggest OST 
reduces re-incarceration rates by 20% (AHR: 0.80, 95% CI: 0.71-0.90)(25) or 34% (AOR: 0.66, 95% 
CI: 0.58-0.76)(26), respectively, with other studies suggesting similar reductions in the incidence of 
criminal convictions(22-24). We, therefore, assume that OST reduces incarceration by 10-42% (range 
from confidence intervals for two estimates above). We assume PWID inject for 5-25 years. 
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For each of the 5,000 incarceration-related parameter sets obtained from step 1, parameter values for 
the transmission component of the model were sampled from their probability distributions (Table 2). 
For each of these 5,000 full parameter sets, the time-varying number of individuals initiating injecting 
annually and their cessation rate were calibrated (using nonlinear least-squares methods) to give the 
estimated PWID population size for Perry County in 2009 (700+/-20%, analysis for this project), while 
assuming up to an 8-fold increase in the number of individuals initiating injecting over 1990-2000, 
consistent with data(28) (see supplementary materials), with initiation of injecting assumed to be 
constant after 2000.  OST recruitment and loss to follow-up rates were then calibrated (using nonlinear 
least-squares methods) to sampled values of OST coverage level and average duration, while assuming 
that discontinuation of OST upon incarceration also contributes to loss to follow-up. Finally, the 
community HCV transmission rate and increased risk for currently/recently incarcerated PWID was 
calibrated (using nonlinear least-squares methods) to fit the model to the sampled antibody HCV 
prevalence (52.2-63.6%) and IRR (1.36-5.77), assuming that the HCV epidemic was stable prior to 
1990 when the initiation rate of PWID increased. Model fits were accepted, and subsequently used in 
the model analyses, if the projected HCV incidence among all PWID for 2011 was within the 95% 
confidence intervals for the estimated HCV incidence (14.9–23.7 per 100py) from the SNAP cohort for 
2009-2014. 
 
Model analyses 
Contribution of incarceration to HCV transmission amongst PWID 
The calibrated model was firstly used to project the contribution or “population attributable fraction” 
(PAF) of incarceration to current HCV transmission amongst PWID in Perry County. This was done 
by comparing the number of incident infections that occurred from 2020-2030 in the status quo 
scenario, which included an elevated risk of HCV transmission amongst currently incarcerated PWID 
and recently released PWID, with how many that would occur if incarceration had no effect on 
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transmission risk from 2020-2030. This was modelled by removing the excess HCV transmission risk 
amongst currently incarcerated and recently released PWID from 2020 onwards. Both scenarios 
assumed current low levels of OST and no NSP. The projected relative reduction in incident infections 
over 10 years was defined as the PAF of incarceration.  
 
Impact of scaling-up OST and NSP and reducing incarceration rates amongst PWID 
The model was then used to project the 10-year impact (2020-2030) of several intervention scenarios 
(S1-S4) which included scaling-up community harm reduction, various aspects of prison-based OST, 
and/or reducing incarceration rates for PWID to simulate what may occur with decriminalization (S5-
S7). For scenarios where we assume some coverage of NSP, an average duration on NSP of 9.1-10.7 
months was used based on data from a three-city study in the U.S.(29) (see supplementary materials). 
Prison NSP was not considered. Specifically, modelled scenarios are as follows:  
Status quo Scenario: Community OST coverage remains low with no NSP. 
Scenario S1*: Scale-up community OST to 50% coverage amongst community PWID, but no retention 
upon incarceration. 
Scenario S1: Scale-up community OST and NSP to 50% coverage amongst community PWID, but no 
retention upon incarceration.  
Scenarios S2/S2*: Scenario S1/S1* plus retain PWID on OST upon incarceration. Prison OST is 
assumed to have the same retention rate as community OST, but all leave OST on release. 
Scenarios S3/S3*: Scenario S2/S2* plus recruit incarcerated PWID onto OST at the same rate as 
community PWID. 
Scenarios S4/S4*: Scenario S3/S4* plus retain all PWID on OST for 6 months following release, 
defined as ‘Comprehensive harm reduction’. 
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Scenario S5: Scenario S4 plus assume drug use is decriminalized.  We model decriminalization similar 
to the Portuguese model such that PWID would not be incarcerated for drug possession-based charges 
but instead would be referred to voluntary treatment. As an illustrative example, due to a lack of data 
on offences leading to incarceration among PWID in Kentucky, we assume half of all incarceration 
events are due to possession and that halve of those referred to OST would start treatment. Specifically, 
we assume that (re-)incarceration rates are reduced by half, and 50% of PWID that would have been 
incarcerated are diverted onto OST (i.e. 50% are incarcerated, 25% remain in the community off OST, 
25% remain in the community but are diverted onto OST). 
 
The impacts of these scenarios were estimated by comparing the percentage of incident HCV infections 
averted over the 10-year period 2020-2030. The model was also used to consider how the projected 
impacts would differ if there was no effect of OST on rates of incarceration and re-incarceration. 
 
Uncertainty analysis 
A linear regression analysis of covariance (ANCOVA) was undertaken to determine which parameter 
uncertainties contribute most to uncertainty in the model projections of the impact of the most 
comprehensive community and prison harm reduction (S4). The proportion of each model outcome’s 
sum-of-squares contributed by each parameter was calculated to estimate the importance of individual 
parameters to the overall uncertainty.  
Results 
Status quo model projections 
The model suggests that 21.9% (95% credible interval (CrI): 17.9-27.6%) of PWID are currently 
incarcerated in 2019, with an initial incarceration rate of 23.8% (19.3-27.8%) per year and a subsequent 
re-incarceration rate of 127.0% (109.5-144.5%) per year, i.e. average time to re-incarceration of 9.4 
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months. The model suggests that on average PWID inject for 8.3 years (5.2-12.9 years), during which 
time they are incarcerated 6.8 times (4.0-11.2). Figure 2 shows the fit of the incarceration sub-model to 
available incarceration data from the SNAP cohort. Overall, the model also suggests that PWID are 
incarcerated for 22.2% (18.2-28.1%) of their injecting career (1.8 years; 1.0-3.2 years) and are in the 
post-release higher transmission risk period for 24.9% (22.8-26.8 %) of their time. 
 
The status quo projections suggest that the PWID population has increased by 47.7% (29.3-141.4%) 
over 1990-2020 (Figure 3), from 314.1 (217.5-573.9) to 771.3 (605.1-946.0). As a consequence of the 
increase in initiation of injecting, the model projects that HCV chronic prevalence and incidence 
declined by about 40% over 1990-2000, to 41.6% (38.4-44.8%) and 15.5 (13.3-20.7) per 100py in 2002, 
respectively. HCV chronic prevalence and incidence then increased to 51.9% (44.6-58.2%) and 19.3 
(17.2-22.9) per 100py in 2020, and will increase further by 2030 (Figure 3). 
 
Figure 3 here 
 
 
Contribution of incarceration to HCV transmission amongst PWID 
The model projects that over 2020-2030, removing the effect of incarceration (and recent release) on 
elevating HCV transmission would prevent 42.7% (15.0-67.4%) of new HCV infections, reducing the 
number of new HCV infections in PC from 723.0 (550.9-949.6) to 413.7 (224.8-673.7). Hence, 
incarceration of PWID contributes two-fifths of on-going HCV transmission amongst PWID or the PAF 
of incarceration is 42.7%. Importantly, removing the effect of incarceration reduces HCV incidence by 
57.5% (20.7-81.5) by 2030, with HCV incidence decreasing to 8.2 (3.6-15.5) per 100py. 
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Impact of scaling-up harm reduction 
Scaling-up OST and NSP to 50% coverage amongst community PWID (S1) could avert 28.5% (20.0-
37.4%) of incident HCV infections over 2020-2030 (Figure 4) reducing HCV incidence by 40.4% 
(28.0-53.5%) to 11.5 (9.2-14.3) per 100py. This impact increases to 32.7% (24.5-41.2%) of HCV 
infections being averted if PWID are retained on OST when incarcerated (S2), increasing to 36.4% 
(27.7-44.9%) if incarcerated PWID are also recruited onto OST in prison (S3), and 45.3% (35.9-54.1%) 
if PWID are also retained on OST for 6 months upon release from prison/jail (“comprehensive harm 
reduction”; S4). This results in a relative 60.0% (43.7-87.8%) greater overall coverage of OST (Figure 
5) and 57.7% (35.4-98.6%) greater impact than was achieved from just scaling-up OST and NSP 
amongst community PWID (Figure 4). In the comprehensive harm reduction scenario S4, HCV 
incidence would reduce by 61.3% (49.6-72.4) by 2030 (to 7.5 (5.6-9.8) per 100py) compared to the 
status quo projections (Figure 3). Importantly, compared to a scenario where just community OST is 
scaled (S1*), the added components of prison OST in scenario S4* result in a doubling in impact 
(104.6% (69.8-166.6%) increase) in terms of infections averted (Figure 4). 
 
Figure 4 here 
 
If OST has no effect on incarceration rates from 2020 onwards, then reduced coverage levels of OST 
and NSP would occur among community PWID , 47.4% (44.7-49.1%) and 48.2% (47.1-49.3%), 
respectively, instead of 50% amongst community PWID for scenario S1 in 2030, with 14.9% (5.7-
28.6%) less infections being averted. This effect reduces for the scenarios where incarcerated PWID 
also access OST, with 5.9% (2.1-13.0) less infections averted for scenario S4. In other words, if OST 
reduces incarceration, then the percentage of HCV infections averted due to OST in the community 
increases relatively by 2.1-14.9% or 6.0-40.1% depending on whether OST is scaled-up in prisons or 
not, respectively. 
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Impact of decriminalisation 
When in addition to comprehensive harm reduction (S4), we also assume decriminalisation 
occurs from 2020, then 56.8% (45.3-64.5%) of incident HCV infections over 2020-2030 could 
be prevented if incarceration rates for PWID are halved and 50% of these PWID are diverted 
to OST (S5). This is partly due to the coverage of NSP increasing because it is not being 
disrupted by periods of incarceration. Interestingly, similar impact is achieved for this scenario 
if there was no diversion to OST because OST coverage levels are already high. Conversely, 
diverting PWID to OST from prison is more important if community interventions are limited 
as they currently are. In this scenario, diverting 50% of to-be incarcerated PWID to OST could 
prevent 15.2% (7.0-22.3) of incident HCV infections over 2020-2030, compared to 12.1% (3.3-
19.7) if decriminalisation just halved incarceration rates. 
 
Uncertainty analysis 
Analysis of covariance indicated that uncertainty in the reduced risk of acquiring HCV whilst on OST 
(42.3%) or NSP (41.7%), the rate of mortality and cessation (7.2%) and the OST loss to follow-up rate 
(4.2%) contributed most to the variability in the impact of scaling-up OST and NSP to comprehensive 
harm reduction (S4). No other model parameters contributed more than 2% to the variability 
(Supplementary Figure S4). 
 
Figure 5 here 
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Discussion 
Main findings 
Due to frequent incarceration and elevated acquisition risk associated with incarceration and recent 
release, our modelling suggests incarceration could be contributing two-fifths (42.7%) of ongoing HCV 
transmission amongst PWID in Perry County. If this elevated risk could be prevented, HCV incidence 
could be reduced by 57.5% by 2030. Because of negligible coverage of OST and NSP in this setting, 
scaling-up these interventions to 50% coverage among community PWID could also avert a quarter 
(28.5%) of incident HCV infections over 2020-2030. However, the impact of these interventions is 
hindered by the frequent incarceration of PWID. Indeed, if PWID were also retained and recruited onto 
OST while incarcerated and retained on OST following release then nearly half (45.3%) of all incident 
HCV infections could be prevented. Decriminalisation could also be important, with a halving in 
incarceration rates increasing impact with 56.8% of infections being prevented. The diversion of to-be 
incarcerated PWID to OST could also be an important strategy but only if OST provision in prisons is 
low.  
 
Strengths and Limitations 
This study presents the first analysis of the impact of HCV prevention interventions for both community 
and incarcerated PWID in a U.S. setting, and the first to estimate the contribution of incarceration to 
HCV transmission in a U.S setting. The main strength of this study is the use of detailed data from Perry 
County to inform model parameterisation, including context specific data on mortality and OST 
retention. Despite this, the study still had limitations. 
 
Firstly, the findings may not be generalisable to urban U.S. or other high-income country settings as 
the model was parameterised to a rural county in Appalachian Kentucky, which has high rates of 
incarceration (86% PWID ever incarcerated) and low intervention coverage. Many cities in the U.S. 
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and other high-income countries have much higher levels of intervention coverage(12, 30) and some 
already have OST in prison(31); less impact would be achieved from scaling-up interventions in these 
settings. Furthermore, the model simulates an increasing injecting population and HCV epidemic, 
which although consistent with the growing epidemic of prescription opioid abuse in the U.S., is not 
applicable to many other settings(32). There is also likely to be other variability across U.S. settings 
which may affect the generalisability of these results, particularly other differences between urban and 
rural settings. This could include duration of injecting, which is likely to be less in rural settings than 
urban settings, and lower levels of substance abuse treatment in rural areas(33), both of which could 
affect the impact of scaling-up prevention interventions(34).  
 
Secondly, uncertainty exists over the magnitude and duration of the heightened risk related to 
incarceration. Whilst we used an empirical estimate from a cohort in Perry County, only those that 
reported incarceration in the last 30 days before the interview, which were on average 6 months apart, 
were classified as exposed to incarceration in our analyses. This will have resulted in some incarceration 
events being missed and allocated incorrectly because they occurred over 30 days before the interview, 
likely resulting in us under-estimating the elevated HCV transmission risk related to incarceration and 
so the contribution of incarceration to HCV transmission in this setting. Furthermore, we assumed the 
same increase in risk during periods of incarceration and the 6-month period following release, as we 
were unable to separate the risk associated with these two periods in the cohort. If, however, the risk in 
prison is lower than the period following release, then the risk following release would need to be higher 
to reproduce the observed heightened risk of HCV acquisition associated with recent incarceration, 
giving a larger impact of OST after release than modelled but a similar contribution of incarceration to 
HCV transmission. 
 
Thirdly, available data from the SNAP cohort could not distinguish between detention in prison or jail, 
although most incarceration events within this cohort are thought to be within jails. The inability to 
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distinguish between these types of incarceration and the possible under-sampling of those who have 
longer times in incarceration may have led to an underestimation of the average duration of detention, 
and so the impact of prison-based OST. Furthermore, it is possible that the increase in risk following 
release from prison or jail may differ, although data was lacking. However, evidence from Montreal 
suggests that the effect of recent incarceration is similar by incarceration type (jail or prison)(35). 
 
Fourthly, although much of the data used to parameterise the model is specific to Perry County, some 
were acquired from elsewhere. For instance, rates of leaving NSP were unavailable for this setting due 
to there currently being negligible NSP in Perry county. The NSP exit rate, therefore, was parameterised 
using data from other U.S. sites(29). It is likely that the average duration in contact with NSP will differ 
based on the characteristics of the NSP initiated in Perry County, including opening times, location, 
and the range of services provided. Future analyses should consider locally specific data. 
 
Fifthly, baseline model fits assume no NSP. In practice, an NSP has been operating in Perry County 
since 2018 with limited opening hours; 4 hours a week at first which has now been expanded to 9am to 
2pm, four days a week. Based on the average frequency of injecting (estimated as 26-44 times per 
month based on SNAP cohort data) and the number of needles distributed since 2018 (96,328), we 
estimate that 62 syringes have been distributed per PWID per year in Perry County. At best, this means 
that 91-154 (12-20% of PWID in Perry County) PWID could obtain enough needles to ensure all 
(100%) their injections are safe. This is a low coverage that would have a small impact on HCV 
transmission(17). Therefore, given the recency of the NSP and its low coverage, our baseline model 
assumed no NSP. Our first intervention scenario incorporates a scale-up in NSP coverage to 50% from 
2020, demonstrating the impact that further NSP expansion will have in this setting. 
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Finally, whilst it is widely accepted that OST is effective at reducing criminal activity(18-20, 36), the 
extent to which this translates to a reduction in incarceration has only been estimated in two studies(25, 
26). Since the effect of OST on reducing incarceration differed widely between these studies, we 
considered a wide range in our analysis. As the effect of OST on incarceration rates may depend on 
numerous factors, including the proportion of incarcerations that are due to drug-related crime, future 
analyses should consider context-specific estimates for this parameter.  
 
Comparisons with existing studies 
This analysis is consistent with previous modelling of the contribution of incarceration to HCV and 
HIV transmission in Scotland(16) and Ukraine(37). As with these prior studies, this work finds that 
incarceration is likely to be an important contributor to HCV transmission amongst PWID. Previous 
modelling has considered the cost-effectiveness of prison-based HCV treatment in the US(38, 39), with 
only one study considering the impact on HCV transmission(39). Our modelling is consistent with that 
modelling(39) and others(16) in showing that prison-based prevention and treatment interventions can 
reduce HCV transmission in the community. This work is also consistent with previous modelling 
studies evaluating the impact of OST and NSP in the community(40). This analysis adds to these by 
showing that if OST is not provided for incarcerated PWID, as is currently the case in the U.S., the 
impact of scaling-up community OST and NSP will be limited by high levels of incarceration, with this 
being compounded by elevated HCV transmission risk during incarceration and following release. This 
agrees with previous modelling of HIV in Ukraine(37) that showed the important prevention benefit of 
providing OST for incarcerated PWID and ensuring retention following release. Indeed, our study 
highlights that retaining PWID on OST upon incarceration, enrolling incarcerated PWID on OST and 
retaining them upon release can achieve much greater (62% more) impact than just scaling-up OST and 
NSP in the community. This is consistent with our recent modelling that highlighted the importance of 
scaling-up OST in prisons alongside the community for reducing mortality among PWID in Kentucky 
and other settings(41). Lastly, this is the first modelling study to quantify the additional prevention 
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benefits that may occur due to PWID on OST having reduced rates of incarceration, which suggests it 
could increase the impact of OST by up to 40.1%. 
 
Implications 
The findings add to a growing body of evidence that suggests incarceration is an important contributor 
to HCV transmission amongst PWID, adding new evidence for a U.S. setting with very high levels of 
incarceration. In contrast to many settings, community coverage levels of OST are very low and NSP 
has only just been initiated in Perry County, so the detrimental effect of incarceration in Perry County 
is unlikely to be due to reduced coverage of harm reduction interventions among incarcerated or 
recently incarcerated PWID. Similarly, few PWID (5.6% in past 3 years) experience homelessness in 
Perry County(10), and so it is unlikely that homelessness plays a role in elevating HCV transmission 
following prison release. For developing future interventions, it is important to investigate the possible 
mechanisms by which incarceration elevates HCV transmission in Perry County. This is crucial for 
intervention development and for advocating for decriminalisation, which our analysis suggests could 
be a powerful public health strategy in the U.S. 
 
To our knowledge, this is the first study to assess the possible impact on HCV transmission of OST 
reducing incarceration. Our findings suggest important prevention benefits (up to 40.1% more HCV 
infections averted) could result from this effect, although our projections are uncertain. It is important 
that further studies evaluate this effect of OST on incarceration so that its additional prevention benefits 
can be quantified better. This is also important because previous economic analyses have shown that 
reductions in crime and incarceration are crucial for determining the cost-effectiveness of OST(42, 43). 
 
International evidence has shown that prison-based OST is associated with reductions in injecting 
risk(44), can significantly reduce HCV incidence amongst incarcerated PWID, as suggested by the 5-
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times lower HCV incidence among PWID on MMT compared to PWID not on MMT in a Spanish 
prison(45) and the approximate three-quarter reduction in HCV incidence after the introduction of OST 
in Scottish prisons(45-47),  and reduces mortality amongst opioid dependent prisoners; both during 
incarceration(48) and following release(49, 50), a period that is otherwise associated with elevated risk 
of drug-related deaths(51). However, OST is abruptly stopped upon incarceration in most U.S. 
jurisdictions(52), with exceptions sometimes made for pregnant women(53) or people with HIV(52). 
In contrast, in many Western European countries, OST is continued and also initiated in prison(31). 
Our findings suggest the continuation of OST upon incarceration, recruitment onto OST in prisons and 
retention on OST following release are crucial for maximising the impact of OST on HCV transmission. 
Without such a comprehensive approach to harm reduction, periods of high transmission risk associated 
with current and recent incarceration will persist, which could undermine future efforts to achieve HCV 
elimination through scaled-up harm reduction and HCV treatment. A comprehensive approach to harm 
reduction, which includes prison-based OST, could be a strong platform for achieving HCV 
elimination, and would optimise the impact of HCV treatment. 
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Table 1: Prior and posterior model parameter ranges for the incarceration sub-model. 
Parameter Prior Distribution Posterior 
parameter 
range 
Source/notes 
Average time in prison per 
incarceration (mths)  
Normal 3.4 (95% CI: 
2.7–4.1) truncated to 95% 
confidence interval. 
2.7-4.1 SNAP cohort 
Percentage of PWID initiating 
injecting when 
 
 
Uniform [43.5-62.7%] 
Uniform prior (0,1-𝑝1). 
𝑝3 = 1 − 𝑝1 − 𝑝2  
  
Prior for 𝑝1 is from SNAP 
data analysis.  
Uninformative prior fo𝑟 𝑝2. 
 Never incarcerated (𝑝1) 43.5-50.8 
 Incarcerated (𝑝2) 0.0-56.1 
 Previously incarcerated (𝑝3) 0.0-56.1 
Incarceration rate per year Uniform [0,1] 0.17-0.29 Uninformative prior 
Re-incarceration rate per year  Uniform [0,2] 1.0-1.5 Uninformative prior 
Mean number of 
incarcerations amongst PWID 
initiating injecting  
Uniform [1,7] 2.0-3.8 Uninformative prior. Used in 
model calibration only – not 
in final model. 
 
  
  
 
29 
Table 2: Full model parameters obtained from literature and data analyses. 
Parameter Range of 
parameter 
values 
Source/Notes 
PWID and HCV-related parameters 
Anti-HCV prevalence amongst 
community PWID  
58.0% (95%CI: 
52.2–63.6) 
SNAP cohort. Sampled from normal 
distribution truncated to 95% CI. 
Average proportion of infections 
that spontaneously clear 
0.26 (95%CI: 
0.22-0.29) 
(54) Sampled from uniform distribution. 
Rate at which PWID initiate 
injecting (Per year) 
Varied over time Calibrated to PWID population size in 
2009.  
Factor increase in initiation rate of 
injecting drug use in 1990-2000 
1.02-6.32 Calibrated so that among current PWID in 
2009 there would be 8 times more PWID 
that started injecting in 2000 than in 1990. 
PWID population size in 2009 560-840 SNAP data analysis estimates a PWID 
population of 700. 
Sampled from uniform distribution. 
Mortality rate (Per 10,000 person 
years) 
50-130 SNAP data analysis. Sampled from 
Poisson distribution with rate 88. 
Average duration of injecting in 
years 
5-25 Young expanding population of injectors 
so uncertainty in duration of injecting - 
wide range assumed with uniform 
distribution. 
Rate ratio for acquiring HCV if 
currently or recently incarcerated. 
2.80 (95%CI: 
1.36-5.77) 
 
(11) Sampled from lognormal distribution, 
truncated to 95% CI. 
Harm Reduction parameters 
Community OST loss to follow-up 
rate (per year) 
0.44-2.90 SNAP data analysis gives overall OST exit 
rate 1.3-3.5 per year. Community OST 
loss to follow-up rate is calibrated to give 
this OST exit rate, sampled from uniform 
distribution 
NSP loss to follow-up rate (per 
year) 
1.12-1.32 Estimated from (29). See supplementary 
materials. 
OST recruitment rate (Per Year) Model calibrated  Varied to give coverage of 4.7% (95% CI: 
3.8-5.8%) in 2009 (SNAP data, normal 
distribution) and then increased from 2020 
to give different OST coverage scenarios.  
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Parameter Range of 
parameter 
values 
Source/Notes 
OST start date 1990-1999 Sampled from uniform distribution 
Relative incarceration rates while 
on OST. 
0.58-0.90 Sampled from uniform distribution. 
Details in main text. 
NSP recruitment rate (per Year) Model calibrated No NSP in status quo. Varied to give 
required coverage for intervention. 
Relative risk of acquiring HCV 
while on:  
 (17) Sampled from lognormal distribution, 
truncated to 95% CI. Efficacy while on 
OST and NSP assumed to be product of 
individual effects. Efficacy of OST in 
prison is assumed to be the same as in the 
community. 
 OST only 0.50 (95% CI: 
0.40-0.63) 
 NSP only 0.44 (95% CI: 
0.24-0.80) 
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Figure 1: Model schematics of the incarceration component (a), HCV transmission component (b) 
and harm reduction states (c). 
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Figure 2: Model fits of the incarceration component of the model to (a) the proportion of community 
PWID previously incarcerated and (b) the mean number of incarcerations, by duration of injection. 
Lines represent the median of all fits, with the shaded area representing the 95% credibility interval of 
the fits. Data points estimated from SNAP (circles), with their 95% confidence intervals (whiskers), 
used in the fitting procedure are shown for comparison. 
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Figure 3: Model projections of (a) overall chronic HCV prevalence among all PWID (in the community 
and in prison), (b) chronic HCV prevalence among community PWID, (c) HCV incidence, and (d) 
PWID populations size. Lines represent the median HCV chronic prevalence, HCV incidence and 
PWID population size. The shaded area represents the 95% credibility intervals for status quo 
projections. HCV incidence and prevalence data points are shown for comparison with 95% confidence 
intervals. OST denotes Opioid substitution therapy and NSP denotes Needle and syringe programmes. 
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Figure 4: Impact of scaling-up Opioid substitution therapy (OST) and Needle and syringe programmes 
(NSP) for various scenarios with differing levels of OST scale-up in prisons. Figure 4a shows the 
percentage of incident HCV infections that would be averted over 10 years compared to the status quo 
scenario, while figure 4b shows the relative impact compared to scaling-up OST only in the community 
with (green – Scenario S1) and without (red – Scenario S1*) a concurrent NSP scale-up among 
community PWID. Bars show the median projections, boxes show the interquartile range, while error 
bars show the 95% credibility intervals.  
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Figure 5: OST coverage among community PWID (light grey), incarcerated PWID (medium grey) and 
all PWID (dark grey) for each modelled intervention scenario with differing levels of OST scale-up in 
prisons. Bars show the median projections, while error bars show the 95% credibility intervals.  
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